论文部分内容阅读
目的研究和观察国产重组人白介素-11(rhIL-11)衍生物对化疗所致血小板降低的疗效和不良反应。方法采用自身对照方法,对化疗所致血小板降低的恶性肿瘤患者,第1周期(对照周期)单用化疗,第2周期(治疗周期)采用相同方案化疗+rhIL-11衍生物治疗。rHIL-11衍生物按每日40μg/kg剂量皮下注射,连续10d。结果本组可评价疗效者89例。治疗后血小板计数≤75×109/L者,对照周期为89例,治疗周期为44例,差异有统计学意义(P=0.00);血小板恢复至正常(≥100×109/L)的天数,对照周期中位值为9(1～47)d,治疗周期为5.5(1～18)d,差异有统计学意义(P=0.00)。其中,治疗后血小板≤50×109/L者,对照周期为56例,治疗周期为20例,差异有统计学意义(P=0.00);血小板恢复至正常的天数,对照周期中位值为9(1～31)d,治疗周期为6(3～13)d,差异无统计学意义(P=0.05)。血小板最低值的范围,对照周期为10×109～75×109/L,治疗周期为10×109～310×109/L,中位值分别为44×109/L和83×109/L,差异有统计学意义(P=0.00);从出现血小板最低值到恢复正常的天数,对照周期中位值为6(1～31)d,治疗周期为2(0～13)d,差异有统计学意义(P=0.00)。对照周期和治疗周期出现血小板最低值的序次天数(中位值)分别为第11.3天和第15.3天;输血小板的例数分别为9和1例,次?
Objective To study and observe the efficacy and adverse reactions of domestic recombinant human interleukin-11 (rhIL-11) derivatives on chemotherapy-induced thrombocytopenia. Methods The patients with malignant tumor with thrombocytopenia induced by chemotherapy were enrolled in this study. The first cycle (control cycle) chemotherapy alone and the second cycle (cycle) were treated with the same regimen of rhIL-11 derivative. The rHIL-11 derivative was injected subcutaneously at a daily dose of 40 μg / kg for 10 days. Results This group can evaluate the efficacy of 89 cases. After treatment, the platelet count ≤75 × 109 / L, the control cycle was 89 cases, the treatment cycle was 44 cases, the difference was statistically significant (P = 0.00); platelets returned to normal (≥100 × 109 / L) days, The median of the control period was 9 (1-47) days, and the treatment period was 5.5 (1-18) days. The difference was statistically significant (P = 0.00). Among them, the treatment of platelets ≤ 50 × 109 / L, the control cycle was 56 cases, the treatment cycle was 20 cases, the difference was statistically significant (P = 0.00); platelets returned to normal days, the median control period was 9 (1 ~ 31) d, the treatment period was 6 (3 ~ 13) d, the difference was not statistically significant (P = 0.05). The range of the lowest platelet count was 10 × 109 ~ 75 × 109 / L and the treatment period was 10 × 109 ~ 310 × 109 / L, the median was 44 × 109 / L and 83 × 109 / L, respectively (P = 0.00). The mean value of the control period was 6 (ranged from 1 to 31) days and the treatment period was 2 (ranged from 0 to 13) days, from the lowest value of platelets to the normal number of days. The difference was statistically significant Meaning (P = 0.00). The number of sequential days (median) of platelet counts at the control and treatment cycles was day 11.3 and day 15.3, respectively; the number of platelets transfused was 9 and 1, respectively,